Amsterdam, the Netherlands and Orlando, U.S. – At the 2018 American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing cardiovascular care solutions that make the management of patients more efficient and effective. By designing intelligent technologies and services that help clinicians to deliver a consistent standard of care, optimize care pathways and integrate workflows, Philips is enabling better patient and population outcomes.

“As a leading innovator in cardiovascular care, we are committed to support care providers and their patients with integrated solutions to address their biggest challenges,” said Bert van Meurs, Business Leader, Image Guided Therapy. “By seamlessly connecting data, technology and people across the health continuum, we’re bridging the gap in patient flow before entrance to the hospital and after discharge, helping to reduce costs and achieve optimal outcomes for patients.”

At ACC.18 Philips will also announce the presentation of new one-year follow-up DEFINE FLAIR trial data on the comparative cost effectiveness of using an iFR-guided strategy in the assessment of coronary blockages when compared to an FFR-guided strategy. This is intended to build on the DEFINE FLAIR trial data announced during ACC.17 [1], which found that iFR-guided treatments offer a 10 percent reduction in procedural time versus FFR-guided treatments, while reducing patient discomfort by 90 percent. iFR technology is proprietary to Philips.
Philips’ image-guided therapy solutions comprise interventional imaging systems, smart devices, software and services that enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment. On-site at ACC.18 Philips is exhibiting a range of integrated solutions for interventional cardiovascular procedures, including:

· Azurion, Philips’ next generation image-guided therapy platform, which enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.

· New instant wave-Free Ratio (iFR) technology, iFR Roadmap [2], exclusive to Philips' interventional labs, which enables physicians to navigate coronary arteries and corresponding iFR data in real time.

· Philips’ SyncVision iFR co-registration solution, which couples iFR physiology measurement pull-back results to the coronary angio, which can be utilized in the stenting process when lesions are more complex.

Cardiology Homepage